GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.670
-0.170 (-9.24%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Company Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.

Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.

GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

GRI Bio, Inc.
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 4
CEO W. Hertz

Contact Details

Address:
2223 Avenida de la Playa, Suite 208
LA Jolla, California 92037
United States
Phone 619 400 1170
Website gribio.com

Stock Details

Ticker Symbol GRI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001824293
ISIN Number US3622AW2059
Employer ID 82-4369909
SIC Code 2834

Key Executives

Name Position
Dr. W. Marc Hertz Ph.D. Co-Founder, Chief Executive Officer, President and Director
Dr. Vipin Kumar Chaturvedi Ph.D. Co-Founder and Chief Scientific Officer
Leanne M. Kelly Chief Financial Officer and Corporate Secretary
Dr. Albert Agro Ph.d. Co-Founder and Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 16, 2025 8-K Current Report
Apr 7, 2025 SCHEDULE 13G Filing
Apr 2, 2025 424B4 Prospectus
Apr 2, 2025 8-K Current Report
Apr 1, 2025 EFFECT Notice of Effectiveness
Mar 26, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 25, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Mar 17, 2025 8-K Current Report
Mar 14, 2025 DRS [Cover] Draft Registration Statement
Mar 14, 2025 10-K Annual Report